Atea Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | — | $351.4 |
| Operating income | -$180.9 | -$192.9 | -$164.2 | -$130.7 | $138.4 |
| Net income | -$158.3 | -$168.4 | -$136.0 | -$115.9 | $121.2 |
| Cash Flow Statement | |||||
| Free cash flow | — | — | — | -$122.9 | -$87.0 |
| Share repurchases | $25.5 | $0.0 | — | — | — |
Shares outstanding 80.0M · Free float 79.5%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.